Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pulsatile controlled-release tablet containing fluticasone furoate and vilanterol and preparation method thereof

A technology of fluticasone furoate and controlled-release tablets, which is applied in the field of pulse controlled-release tablets containing fluticasone furoate and vilanterol and its preparation, which can solve problems such as complicated operation steps, toxic and side effects of preparations, and difficulty in achieving inhalation speed

Inactive Publication Date: 2016-07-27
HYBIO PHARMA
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the dry powder inhaler still cannot solve the contradiction between increasing the lung deposition rate and reducing the patient's maximum inspiratory flow rate
This is quite disadvantageous for patients with COPD, there are cases of poor patient compliance
Moreover, the use of this dosage form will be affected by the age or physiological state of the patient, and it is difficult to use it for infants with weak respiratory muscles, the elderly and patients with severe asthma attacks, because some of these patients are difficult to reach The inhalation speed required by the inhaler makes it difficult for some to learn the correct use of dry powder inhalers
In addition, the existing dry powder inhaler products also have the disadvantages of high cost and complicated operation steps.
[0005] On the other hand, chronic obstructive pulmonary disease (COPD) and asthma attack usually in the early morning and early morning, relieve during the day, and existing common tablet can't guarantee blood drug concentration when 3-4 o'clock in the morning, although sustained-release tablet can Maintain the blood drug concentration for a long time, but the blood drug concentration has peaks and valleys, which may easily lead to the occurrence of toxic and side effects of the preparation and affect the safety of medication

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pulsatile controlled-release tablet containing fluticasone furoate and vilanterol and preparation method thereof
  • Pulsatile controlled-release tablet containing fluticasone furoate and vilanterol and preparation method thereof
  • Pulsatile controlled-release tablet containing fluticasone furoate and vilanterol and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] Example 1. Formulation and preparation of pulse controlled-release tablets of fluticasone furoate and vilanterol

[0035] 1. Tablet core prescription (20000 tablets)

[0036] a. Prescription for immediate release: 10.0g fluticasone furoate, 2.0g vilanterol, 20.0g low-substituted hydroxypropyl cellulose, 200.0g lactose, 2.0g povidone K30.

[0037] b. Prescription for controlled release: 20.0g fluticasone furoate, 10.0g vilanterol, 30.0g low-substituted hydroxypropyl cellulose, 250.0g lactose; 40.0g Eudragit L100.

[0038] C. Lubricant: 3.0g magnesium stearate

[0039] 2. Sponge prescription

[0040] 800.0 g hydroxypropyl methylcellulose (HPMC), 2200.0 g lauryl alcohol, 20.0 g magnesium stearate.

[0041] 3. Preparation method:

[0042] (1) Preparation of tablet core

[0043] a. Preparation of immediate-release granules: mix fluticasone furoate, vilanterol, low-substituted hydroxypropyl cellulose, and lactose evenly, spray 2% povidone k30 aqueous solution on the powd...

Embodiment 2

[0050] Example 2. Formulation and preparation of pulse controlled-release tablets of fluticasone furoate and vilanterol

[0051] 1. Tablet core prescription (20000 tablets)

[0052] a. Prescription for immediate release: 20.0g fluticasone furoate, 4.0g vilanterol, 20.0g croscarmellose sodium, 100.0g mannitol, 100.0g microcrystalline cellulose, 3.0g povidone k30.

[0053] b. Prescription for controlled release: 30.0g fluticasone furoate, 16.0g vilanterol, 40.0g croscarmellose sodium, 100.0g mannitol, 200.0g microcrystalline cellulose, 45.0g Kollicoat MAE30DP.

[0054]c. Lubricant: 4.0g magnesium stearate sodium fumarate

[0055] 2. Sponge prescription

[0056] 1000.0g Sodium Alginate, 3200.0g Myristyl Alcohol, 24.0g Magnesium Stearate Sodium Fumarate.

[0057] 3. Preparation

[0058] (1) Preparation of tablet core

[0059] a. Preparation of immediate-release granules: mix fluticasone furoate, vilanterol, croscarmellose sodium, mannitol, and microcrystalline cellulose, and ...

Embodiment 3

[0066] Example 3. Formulation and preparation of pulse-controlled release tablets of fluticasone furoate and vilanterol

[0067] 1. Tablet core prescription (20000 tablets)

[0068] a. Prescription for immediate release: 30.0g fluticasone furoate, 10.0g vilanterol, 10.0g sodium starch glycolate, 10.0g low-substituted hydroxypropyl cellulose, 150.0g mannitol, 150.0g lactose, 4.0g hydroxy Propyl methylcellulose.

[0069] b. Prescription for controlled release: 40.0g fluticasone furoate, 20.0g vilanterol, 44.0g sodium starch glycolate, 200g mannitol, 100g microcrystalline cellulose, 100g lactose, 50.0g Kollicoat MAE100P.

[0070] c. Lubricant: 4.0g magnesium stearate, 2.0g talc.

[0071] 2. Sponge prescription

[0072] 1000.0g sodium alginate, 200.0g hydroxyethyl cellulose, 5600.0g cetyl alcohol, 30.0g magnesium stearate.

[0073] 3. Preparation

[0074] (1) Preparation of tablet core

[0075] a. Preparation of immediate-release granules: mix fluticasone furoate and vilante...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Diameteraaaaaaaaaa
Login to View More

Abstract

The invention provides a pulsatile controlled-release tablet containing fluticasone furoate and vilanterol. The pulsatile controlled-release tablet can reach plasma concentration at midnight and early morning, so the purpose of chrono-chemotherapy is achieved. The pulsatile controlled-release tablet comprises a floating layer and a tablet core. The floating layer uses hydrophilic high molecules and fatty alcohol as adjuvant materials, so the floating layer can retain for a certain period of time in the stomach; when the tablet contacts with gastric juice, the surface of the floating layer hydrates to form gel, so the size of the tablet becomes larger; when the gel is smaller than the concentration of the gastric juice, the tablet is allowed to float above contents in the stomach; and the tablet core appears along with dissolution of the skeleton of the floating layer, so drugs are released from the tablet core.

Description

technical field [0001] The invention belongs to the field of medicinal chemistry, and in particular relates to a pulse-controlled release tablet containing fluticasone furoate and vilanterol and a preparation method thereof. Background technique [0002] Bronchial asthma is a chronic inflammatory disease of the airways that involves a variety of cells (such as eosinophils, mast cells, T lymphocytes, neutrophils, airway epithelial cells, etc.) and cell components. This chronic inflammation leads to the generation of airway hyperresponsiveness, usually with widespread and variable reversible airflow limitation, and causes recurrent symptoms such as wheezing, shortness of breath, chest tightness or coughing, often at night and / or in the early morning, Most patients can be relieved spontaneously or after treatment. [0003] Chronic obstructive pulmonary disease (COPD) is a chronic bronchitis and / or emphysema characterized by airflow obstruction, a common chronic disease that ca...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K9/28A61K9/36A61K31/56A61P11/06A61K31/137
Inventor 郑春莲陶安进徐春莲马亚平袁建成
Owner HYBIO PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products